Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy.

BACKGROUND

Previous trials have shown improved efficacy of neoadjuvant treatment when combined with angiotensin II receptor antagonist, losartan in patients with locally advanced pancreatic ductal adenocarcinoma (PDA). However, role of losartan is unknown in metastatic PDA. In this retrospective observational study, we examined the relationship between losartan use at time of diagnosis and continued through chemotherapy treatment with clinical outcomes in patients with metastatic PDA that received chemotherapy.

METHODS

We retrospectively evaluated 114 metastatic PDA patients treated at University of Kansas Cancer Center between January 2000 and November 2019. We compared overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) between patients using losartan at time of their cancer diagnosis and a control group of patients who were not on losartan. A subgroup analysis was performed based on patients who were on a 100 mg dose of losartan along with chemotherapy versus patients treated with chemotherapy (without losartan). Another subgroup analysis was performed based on chemotherapy regimen: Fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) versus Gemcitabine and Abraxane.

RESULTS

No significant difference was found in OS (p=0.466) or PFS (p=0.919) in patients on losartan (median 274 day, 83 day) and control patients (median 279 day, 111 day). No significant difference was found in ORR (p=0.621) or in DCR (p=0.497). No significant difference was found in OS (p=0.771) or PFS (p=0.0604) in losartan patients (median 347 day, 350 day) and control patients (median 333 day, 101 day) treated with FOLFIRINOX. No significant difference was found in OS (p=0.916) or PFS (p=0.341) in losartan (median 312 day, 69 day) and control patients (median 221 day, 136 day) treated with Gemcitabine plus Abraxane. No significant difference was found in OS (p=0.727) or PFS (p=0.790) in 100 mg losartan patients (median 261 day, 84 day) and control (median 279 day, 111 day).

CONCLUSIONS

Patients on losartan at time of diagnosis and continued through chemotherapy treatment had no significant difference in OS, PFS, ORR, DCR than control patients. Subgroup analysis of patients treated with FOLFIRINOX revealed a longer PFS with losartan than control but did not reach statistical significance, likely due to small sample size. Our findings should be validated in a larger cohort to confirm if the benefit of losartan and FOLFIRINOX seen in a neoadjuvant setting for locally advanced cancer also applies to metastatic cancer.

RELEVANCE FOR PATIENTS

This research adds to growing data on the efficacy of angiotensin receptor blocking drugs as adjunctive treatment in addition to chemotherapy in pancreatic cancer with specific focus on metastatic disease.